Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer

26 Jul 2014

Abstract excerpt

// Jorge Franco 1 , Agnieszka K. Witkiewicz 1,2 and Erik S. Knudsen 1,2 1 Department of Pathology , UT Southwestern, Dallas TX 2 Simmons Cancer Center, UT Southwestern, Dallas TX Correspondence: Erik S. Knudsen, email: // Agnieszka K. Witkiewicz, email: // Keywords : RB, CDK4/6, palbocicllb, pancreatic cancer, E2F Received : July 10, 2014 Accepted : July 26, 2014 Published : July 26, 2014 Abstract Pancreatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25156567
DOI: 10.18632/oncotarget.2270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancerPMID 25156567Read ↗

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancerSemantic proximity Read ↗

CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma.Semantic proximity Read ↗

Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21Semantic proximity Read ↗

Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer CellsSemantic proximity Read ↗

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtypeSemantic proximity Read ↗

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic CancerSemantic proximity Read ↗

Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity TestingSemantic proximity Read ↗

Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDACSemantic proximity Read ↗

Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancerSemantic proximity Read ↗

Targeting CDK4/6 in patients with cancerSemantic proximity Read ↗

The application and prospect of CDK4/6 inhibitors in malignant solid tumorsSemantic proximity Read ↗

Biological specificity of CDK4/6 inhibitors: dose response relationship,in vivosignaling, and composite response signatureSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.